This was the stock's fourth consecutive day of gains.
The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its key ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...
Shares have been on the move with the stock up 5.8% over the past month. The stock hit a new 52-week high of $58.22 in the previous session. Vertex has gained 6.2% since the start of the year compared ...
Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...
The polar vortex, a natural atmospheric phenomenon, influences global winter weather by circulating Arctic air. Its expansion ...
In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...